Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 112

Sort by

Sort Order Select

Journal Articles

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

Blood (2025) 146 (Supplement 1): 235.

https://doi.org/10.1182/blood-2025-235

Published: 2025

Journal Articles

Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)

Uwe Platzbecker, Elena Crisa, Sophie Salazar, Thomas Cluzeau, Antonella Poloni, Raquel De Paz Arias, Thibault Comont, Sebastian Grosicki, Aristoteles Giagounidis, Matteo Della Porta, Pellegrino Musto, Mar Tormo, Dominic Brauer, Ana Alfonso-Pierola, Stefania Paolini, Sophie Park, Annelies Weyn, Lionel Ades, Valeria Santini

Blood (2025) 146 (Supplement 1): 5649.

https://doi.org/10.1182/blood-2025-5649

Published: 2025

Journal Articles

Clonal evolution and risk assessment in myelodysplastic syndromes (MDS): A prospective Study of dynamic IPSS-m validation and evolutionary trajectory modeling by the italian MDS foundation (FISIM)

Luca Lanino, Matteo Zampini, Ivan Civettini, Daniele Ramazzotti, Alessia Campagna, Elena Riva, Denise Ventura, Nicole Pinocchio, Pasquale Niscola, Marco Gabriele Raddi, Angela Consagra, Federica Pilo, Antonella Poloni, Mariarita Sciumè, Andrea Patriarca, Stefania Paolini, Carlo Finelli, Andrea Castelli, Pellegrino Musto, Anna Calvisi, Grazia Sanpaolo, Monia Marchetti, Elisa Diral, Germana Beltrami, Carmen Fava, Claudio Fozza, Chiara Frairia, Carmine Selleri, Daniela Barraco, Domenico Pastore, Rosanna Ciancia, Elena Crisa, Enrico Balleari, Susanna Gallo, Vincenzo Pavone, Esther Natalie Oliva, Giulia Maggioni, Ferdinando Frigeri, Gabriele Todisco, Antonio Russo, Alessandro Buizza, Ivan Ferrari, Giulia Figini, Alessandra Crespi, Elisa Calvetti, Chiara Milanesi, Nicla Manes, Francesco Pesce, Saverio D'Amico, Gianluca Asti, Elisabetta Sauta, Guido Sanguinetti, Gastone Castellani, Marilena Bicchieri, Ilaria Naldi, Francesca Ficara, Valeria Santini, Marta Ubezio, Matteo Della Porta

Blood (2025) 146 (Supplement 1): 3842.

https://doi.org/10.1182/blood-2025-3842

Published: 2025

Journal Articles

Thrombocytopenia at diagnosis adversely affects overall and leukemia-free survival in lower-risk MDS patients: A retrospective study from the FISiM registry

Anna Calvisi, Rosangela Filiberti, Daniela Barraco, Massimo Bernardi, Isabella Capodanno, Andrea Castelli, Rosanna Ciancia, Carmen Fava, Carla Fili, Chiara Frairia, Francesco Frattini, Piero Galieni, Pasquale Niscola, Stefania Paolini, Andrea Patriarca, Anna Maria Pelizzari, Grazia Sanpaolo, Carmine Selleri, Francesco Alesiani, Gianni Binotto, Costanza Bosi, Catello Califano, Barbara Castagnari, Elena Crisa, Monica Crugnola, Marco De Gobbi, Matteo Della Porta, Nicola Di Renzo, Dario Ferrero, Carlo Finelli, Carla Foli, Claudio Fozza, Maurizio Frezzato, Ferdinando Frigeri, Gianluca Guaragna, Monia Marchetti, Daniele G. Mattei, Mara Memoli, Paola Minetto, Alfredo Molteni, Pellegrino Musto, Esther Natalie Oliva, Giuseppe Alberto Palumbo, Fabrizio Pane, Giuseppe Pietrantuono, Federica Pilo, Antonella Poloni, Giulia Rivoli, Mariarita Sciumè, Rodolfo Tassara, Mauro Turrini, Letizia Zannoni, Ilaria Naldi, Enrico Balleari, Valeria Santini, Francesco Onida

Blood (2025) 146 (Supplement 1): 2080.

https://doi.org/10.1182/blood-2025-2080

Published: 2025

Journal Articles

A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trial

Blood (2025) 146 (Supplement 1): 3516.

https://doi.org/10.1182/blood-2025-3516

Published: 2025

Journal Articles

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Blood (2024) 144 (Supplement 1): 3800.

https://doi.org/10.1182/blood-2024-210768

Published: 2024

Journal Articles

Venetoclax and Azacitidine for Relapse Prevention in NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial

Blood (2024) 144 (Supplement 1): 2893.

https://doi.org/10.1182/blood-2024-210315

Published: 2024

Journal Articles

Myeloid Differentiation in Myelodysplastic Neoplasms and Leukemic Cells: Role of Azacitidine and Direct Contact with Mesenchymal Stromal Cells

Eleonora Ceneri, Irene Casalin, Alessia De Stefano, Alessandra Cappellini, Lucio Cocco, Stefano Ratti, Lucia Manzoli, Michele Cavo, Miriam Fogli, Sarah Parisi, Stefania Paolini, Marilena Ciciarello, Antonio Curti, Carlo Finelli, Matilde Yung Follo

Blood (2024) 144 (Supplement 1): 6688.

https://doi.org/10.1182/blood-2024-204876

Published: 2024

Journal Articles

Investigating Phosphoinositide-Related and Apoptotic Pathways in Azacitidine and Venetoclax Combination Therapy in Higher-Risk Myelodysplastic Neoplasms and Leukemic Cell Lines

Irene Casalin, Eleonora Ceneri, Alessia De Stefano, Alessandra Cappellini, Andrea Pellagatti, Jacqueline Boultwood, Michele Cavo, Stefano Ratti, Lucia Manzoli, Lucio Cocco, Anna Ferrari, Giorgia Simonetti, Giovanni Martinelli, Miriam Fogli, Stefania Paolini, Sarah Parisi, Antonio Curti, Carlo Finelli, Matilde Yung Follo

Blood (2024) 144 (Supplement 1): 6686.

https://doi.org/10.1182/blood-2024-200842

Published: 2024

Journal Articles

T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2024-205994

Published: 2024

Journal Articles

Absolute Lymphocyte Count As a Novel Prognostic Predictor Compared to Minimal Residual Disease and Molecular Status in Patients with Acute Myeloid Leukemiatreated with Intensive Chemotherapy

Gianluca Cristiano, Jacopo Nanni, Letizia Zannoni, Federico Zingarelli, Federica Ardizzoia, Chiara Sartor, Sarah Parisi, Stefania Paolini, Cristina Papayannidis, Michele Cavo, Antonio Curti

Blood (2024) 144 (Supplement 1): 6116.

https://doi.org/10.1182/blood-2024-209333

Published: 2024

Journal Articles

Bone Marrow Microenvironment As a Potential Key Regulator of Hematopoietic Cells Stemness in Myelodysplastic Syndromes (MDS)

Irene Casalin, Alessia De Stefano, Alessandra Cappellini, Eleonora Ceneri, Martina Lops, Andrea Pellagatti, Jacqueline Boultwood, Michele Cavo, Stefano Ratti, Lucia Manzoli, Lucio Cocco, Marilena Ciciarello, Miriam Fogli, Stefania Paolini, Sarah Parisi, Antonio Curti, Carlo Finelli, Matilde Yung Follo

Blood (2023) 142 (Supplement 1): 6463.

https://doi.org/10.1182/blood-2023-179914

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

Blood (2023) 142 (Supplement 1): 193.

https://doi.org/10.1182/blood-2023-178596

Published: 2023

Journal Articles

T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3 -Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2947.

https://doi.org/10.1182/blood-2023-184741

Published: 2023

Journal Articles

Impact of MTHFR Polymorphisms C677T and A1298C in Acute Lymphoblastic Leukemia and Burkitt Lymphoma Patients Exposed to Methotrexate and Asparaginase

Chiara Sartor, Benedetta Pagano, Soara Menabò, Gianluca Cristiano, Jacopo Nanni, Letizia Zannoni, Federico Zingarelli, Sarah Parisi, Alessandro Broccoli, Stefania Paolini, Pier Luigi Zinzani, Michele Cavo, Cristina Papayannidis, Antonio Curti

Blood (2023) 142 (Supplement 1): 5812.

https://doi.org/10.1182/blood-2023-189495

Published: 2023

Journal Articles

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Blood (2023) 141 (11): 1265–1276.

https://doi.org/10.1182/blood.2022016362

Published: 2023

Includes: Supplemental data

Journal Articles

Venetoclax Rapidly and Strongly Enhances the Phospholipase C Response to Azacitidine Therapy in Myelodysplastic Syndromes

Matilde Y Follo, Alessia De Stefano, Sara Mongiorgi, Irene Casalin, Alessandra Cappellini, Stefano Ratti, Andrea Pellagatti, Miriam Fogli, Michele Cavo, Lucia Manzoli, Lucio Cocco, Jacqueline Boultwood, Sarah Parisi, Stefania Paolini, Antonio Curti, Carlo Finelli

Blood (2022) 140 (Supplement 1): 6905–6906.

https://doi.org/10.1182/blood-2022-163628

Published: 2022

Journal Articles

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

Luca Lanino, Prassede Salutari, Alessandra Perego, Bruno Fattizzo, Marta Riva, Marta Ubezio, Pellegrino Musto, Daniela Cilloni, Esther Natalie Oliva, Maria Teresa Voso, Anna Maria Pelizzari, Antonella Poloni, Isabella Capodanno, Chiara Elena, Claudio Fozza, Fabrizio Pane, Massimo Breccia, Marco De Gobbi, Francesco Di Bassiano, Daniela Barraco, Elena Crisà, Dario Ferrero, Chiara Frairia, Antonella Vaccarino, Davide Griguolo, Stefania Paolini, Martina Quintini, Mariarosaria Sessa, Mauro Turrini, Monica Bocchia, Nicola Di Renzo, Elisa Diral, Cristina Foli, Alfredo Molteni, Ubaldo Occhini, Giulia Rivoli, Carmine Selleri, Roberto Bono, Anna Calvisi, Andrea Castelli, Eros Di Bona, Ambra Di Veroli, Luana Fianchi, Sara Galimberti, Daniele Grimaldi, Monia Marchetti, Marianna Norata, Alessandro Rambaldi, Ilaria Tanasi, Patrizia Tosi, Ilaria Naldi, Valeria Santini, Matteo G. Della Porta

Blood (2022) 140 (Supplement 1): 6945–6948.

https://doi.org/10.1182/blood-2022-164559

Published: 2022

Journal Articles

A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure

Chiara Sartor, Lorenzo Brunetti, Ernesta Audisio, Alessandro Cignetti, Letizia Zannoni, Gianluca Cristiano, Jacopo Nanni, Emanuela Ottaviani, Lorenza Bandini, Sarah Parisi, Stefania Paolini, Sofia Sciabolacci, Valeria Cardinali, Cristina Papayannidis, Michele Cavo, Maria Paola Martelli, Antonio Curti

Blood (2022) 140 (Supplement 1): 9034–9035.

https://doi.org/10.1182/blood-2022-165914

Published: 2022

Journal Articles

Absolute Lymphocyte Count Is an Independent Survival Predictor in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy

Gianluca Cristiano, Jacopo Nanni, Letizia Zannoni, Federico Zingarelli, Chiara Sartor, Sarah Parisi, Stefania Paolini, Cristina Papayannidis, Michele Cavo, Antonio Curti

Blood (2022) 140 (Supplement 1): 11793–11794.

https://doi.org/10.1182/blood-2022-167035

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)

Clonal evolution and risk assessment in myelodysplastic syndromes (MDS): A prospective Study of dynamic IPSS-m validation and evolutionary trajectory modeling by the italian MDS foundation (FISIM)

Thrombocytopenia at diagnosis adversely affects overall and leukemia-free survival in lower-risk MDS patients: A retrospective study from the FISiM registry

A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trial

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Venetoclax and Azacitidine for Relapse Prevention in NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial

Myeloid Differentiation in Myelodysplastic Neoplasms and Leukemic Cells: Role of Azacitidine and Direct Contact with Mesenchymal Stromal Cells

Investigating Phosphoinositide-Related and Apoptotic Pathways in Azacitidine and Venetoclax Combination Therapy in Higher-Risk Myelodysplastic Neoplasms and Leukemic Cell Lines

T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia

Absolute Lymphocyte Count As a Novel Prognostic Predictor Compared to Minimal Residual Disease and Molecular Status in Patients with Acute Myeloid Leukemiatreated with Intensive Chemotherapy

Bone Marrow Microenvironment As a Potential Key Regulator of Hematopoietic Cells Stemness in Myelodysplastic Syndromes (MDS)

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3 -Mutated Acute Myeloid Leukemia

Impact of MTHFR Polymorphisms C677T and A1298C in Acute Lymphoblastic Leukemia and Burkitt Lymphoma Patients Exposed to Methotrexate and Asparaginase

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Venetoclax Rapidly and Strongly Enhances the Phospholipase C Response to Azacitidine Therapy in Myelodysplastic Syndromes

A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure

Absolute Lymphocyte Count Is an Independent Survival Predictor in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only